Aripiprazole augmentation in patients with resistant obsessive compulsive disorder: a pilot study

Area of Science:

• Psychiatry and Pharmacology
• Neuroscience
• Clinical Psychology

Background:

• Obsessive Compulsive Disorder (OCD) often requires augmentation strategies for treatment-resistant cases.
• Selective Serotonin Reuptake Inhibitors (SSRIs) are first-line treatments, but many patients do not achieve remission.
• Antipsychotic augmentation is a recognized approach for refractory OCD.

Purpose of the Study:

• To evaluate the efficacy and tolerability of Aripiprazole as an augmentation agent for treatment-resistant OCD.
• To assess symptom reduction using standardized OCD scales.
• To monitor adverse events associated with Aripiprazole augmentation.

Main Methods:

• A pilot study involving 20 patients diagnosed with treatment-resistant OCD.
• Aripiprazole was added to existing SSRI or clomipramine treatment, with flexible dosing up to 20 mg/day.
• Efficacy measured by Yale-Brown Obsessive Compulsive Scale (Y-BOCS) and Clinical Global Impression-Severity (CGI-S) at 12 weeks.
• Side effects assessed using the Udvalg for Kliniske Undersogelser (UKU) scale.

Main Results:

• All 20 participants completed the 12-week study.
• A statistically significant reduction in Y-BOCS scores was observed from baseline to week 12 (p=0.0001).
• Aripiprazole was generally well-tolerated, with common side effects including akathisia, nausea, and tremors.

Conclusions:

• Aripiprazole appears to be an effective and well-tolerated augmenting agent for patients with treatment-resistant OCD.
• These preliminary findings warrant further investigation in larger, randomized controlled trials.
• Aripiprazole augmentation offers a promising therapeutic option for refractory OCD cases.